[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoma-b-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoma-b-cell":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,42,70,106,130,158,185,216,244,270,305,328,359,380,409,430,461,487,513,536,563,593,617,640,664],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100474850","phase-1-a-phase-12-study-of-stp938-dencatistat-for-adult-subjects-with-relapsedrefractory-b-cell-and-t-cell-lymphomas-100474850",false,"NCT05463263","A Phase 1\u002F2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed\u002FRefractory B-Cell and T-Cell Lymphomas","An Open-Label, First in Human, Phase 1\u002F2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed\u002FRefractory B-Cell and T-Cell Lymphomas","Main Inclusion Criteria:\n\n* Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.\n* Male or female aged ≥ 18 years.\n* Relapsed\u002Frefractory patients with histologically confirmed diagnosis of B cell or T cell lymphoma\n* Must have received at least 2 prior systemic therapies and have no treatment options known to provide clinical benefit\n* Must have measurable disease per Lugano lymphoma classification except for cutaneous T-cell lymphoma (CTCL) which is measured via International Society for Cutaneous Lymphomas (ISCL)\u002F European Organization of Research and Treatment of Cancer (EORTC).\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n* Life expectancy \\> 3 months as assessed by the Investigator.\n* Adequate organ function (bone marrow, hepatic, renal function and coagulation).\n* All toxicities (except alopecia) from prior cancer treatments or procedures must have resolved to ≤Grade 1 or returned to baseline levels prior to enrollment.\n\nMain Exclusion Criteria:\n\n* Pregnant or breastfeeding females and women of child bearing potential or males unwilling to comply with contraception requirements.\n* Known carcinomatous meningitis or central nervous system (CNS) involvement with lymphoma.\n* Active malignancy within 2 years of study enrollment\n* Prior radiation or surgical resection of their lymphoma without additional sites of measurable disease outside of the radiation field or subjects who have received prior radiation or surgical resection of their lymphoma ≤2 weeks prior to the first dose of study drug.\n* Systemic cancer treatments, monoclonal antibody-directed therapies, other investigational agents within 4 weeks before enrollment, or \\\u003C5 half-lives since completion of previous investigational therapy, whichever is shorter.\n* Uncontrolled intercurrent illness.\n* Immunocompromised subjects with increased risk of opportunistic infections or history of opportunistic infection in the last 12 months.\n* Known active or chronic hepatitis B or active hepatitis C virus (HCV) infection.\n* Subjects who have received a live vaccine within 30 days prior to study enrollment or whilst participating in the study.\n* Subjects with corrected QT interval \\>470 msec based on averaged triplicate electrocardiogram (ECG) readings at the Screening Visit using the QT interval corrected for heart rate using Fridericia's method (QTcF).\n* Subjects who received a severe acute respiratory syndrome coronavirus 2 vaccine ≤3 weeks prior to study drug dosing.","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The Phase 1 part of the study is a dose escalation of STP938 as monotherapy.\n\nThe Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.",[27,28],"Lymphoma, B-Cell","Lymphoma, T-Cell","RECRUITING","2026-06-13",{"date":32,"type":33},"2026-06-16","ACTUAL",{"date":35,"type":33},"2022-08-03",{"date":37,"type":20},"2026-12",{"name":39,"class":40},"Step Pharma, SAS","INDUSTRY",15,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100430358","phase-1-study-of-safety-and-efficacy-of-iberdomide-cc-220-and-cc-99282-combined-with-r-chop-to-treat-lymphoma-100430358","NCT04884035","Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma","Inclusion Criteria:\n\n* Participants must satisfy the following criteria to be enrolled in the study:\n\n  1. Is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n  2. Participant has histologically confirmed (per local evaluation) diagnosis of de novo, previously untreated, a-BCL according to 2016 WHO classification.\n  3. Participant has International Prognostic Index (IPI) score 0-5 in Part 1 and IPI 2-5 in Part 2. For the CELMoD and polatuzumab-R-CHP cohort, the subject must also have IPI score 0 to 5 in Part 2A and IPI 2 to 5 in Part 2B.\n  4. Participants must have measurable disease defined by at least one FDG-avid lesion for FDG-avid subtype and one bi-dimensionally measurable (\\> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification (Cheson, 2014).\n  5. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n  6. Participants must have the following laboratory values:\n\n     1. Absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL or ≥ 1.0 x 109\u002FL in case of documented bone marrow involvement (\\> 50% or tumor cells), without growth factor support for 7 days (14 days if peg-G-CSF)\n     2. Hemoglobin (Hb) ≥ 8 g\u002FdL\n     3. Platelets (PLT) ≥ 75 x 109\u002FL or ≥ 50 x 109\u002FL in case of documented bone marrow involvement (\\>50% or tumor cells), without transfusion for 7 days\n     4. Aspartate aminotransferase \u002F serum glutamic oxaloacetic transaminase (AST\u002FSGOT) and alanine aminotransferase \u002F serum glutamate pyruvic transaminase (ALT\u002FSGPT) ≤ 2.5 x upper limit of normal (ULN). In the case of documented liver involvement by lymphoma, ALT\u002FSGPT and AST\u002FSGOT must be ≤ 5.0 x ULN.\n     5. Serum total bilirubin ≤ 2.0 mg\u002FdL except in cases of Gilbert's syndrome, then ≤ 5.0 mg\u002Fdl. Subjects receiving polatuzumab vedotin must have serum total bilirubin \\\u003C 1.5 × ULN (26 μmol\u002FL) (corresponding to mild degree as per National Cancer Institute Organ Dysfunction Working Group \\[NCI ODWG\\] criteria) except in cases of Gilbert's syndrome, then ≤ 3.0 mg\u002Fdl (51 μmol\u002FL).\n     6. Estimated serum creatinine clearance (CrCl) of ≥ 50 mL\u002Fmin using the modification of diet in renal disease (MDRD) formula.\n  7. All participants must:\n\n     1. Have an understanding that the study drug could have a potential teratogenic risk.\n     2. Agree to follow all requirements defined in the Pregnancy Prevention Program for CC-220 or CC-99282 Pregnancy Prevention Plan for Participants in Clinical trials.\n  8. Females of childbearing potential (FCBP) must:\n\n     a. Have two negative pregnancy tests as verified by the investigator prior to starting study therapy.\n  9. Male participants must:\n\n     1. Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study.\n\nExclusion Criteria:\n\n* The presence of any of the following will exclude a participant from enrollment:\n\n  1. Any significant medical condition, active infection (including SARS-CoV-2 suspected or confirmed), laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.\n  2. Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he\u002Fshe were to participate in the study.\n  3. Any other subtype of lymphoma.\n  4. Documented or suspected CNS involvement by lymphoma.\n  5. Persistent diarrhea or malabsorption ≥ Grade 2 (NCI CTCAE v5.0), despite medical management.\n  6. Peripheral neuropathy ≥ Grade 2 (NCI CTCAE v5.0).\n  7. Subjects with a history of progressive multifocal leukoencephalopathy.\n  8. Chronic systemic immunosuppressive therapy or corticosteroids\n  9. Impaired cardiac function or clinically significant cardiac disease, including any of the following:\n\n     a. Left ventricular ejection fraction (LVEF) \\\u003C 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO)\n  10. Major surgery ≤ 2 weeks prior to starting CC-220 or CC-99282; participant must have recovered from any clinically significant effects of recent surgery.\n  11. Any condition causing inability to swallow tablets.\n  12. Known seropositivity for or active viral infection with human immunodeficiency virus (HIV)\n  13. Known chronic active hepatitis B (hepatitis B virus surface antigen \\[HBsAg\\] positive and\u002For hepatitis B core antibody \\[anti-HBc\\] positive with viral DNA positive) or C (positive serology requiring treatment and\u002For with evidence of liver damage) infection\n  14. History of other malignancy, unless being free of the disease for ≥ 3 years; exceptions to the ≥ 3-year time limit include history of the following:\n\n      1. Localized nonmelanoma skin cancer\n      2. Carcinoma in situ of the cervix\n      3. Carcinoma in situ of the breast\n      4. Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor Node Metastasis \\[TNM\\] staging system) or prostate cancer that has been treated with curative intent.\n  15. Hypersensitivity to the active substance or to murine proteins, or to any of the other excipients of rituximab or polatuzumab vedotin.\n  16. Known hypersensitivity to any component of CHOP\u002FCHP regimen.\n  17. Known allergy to thalidomide, pomalidomide, or lenalidomide.",{"count":50,"type":20},224,[23],"This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and\u002For CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 and\u002For CC-99282 and R-CHOP-21 combination has been defined.",[27],[55,56,57,58,59],"Iberdomide","CC-220","CC-99282","Phase 1","B-Cell Lymphoma","2026-06-05",{"date":62,"type":33},"2026-06-08",{"date":64,"type":33},"2021-09-15",{"date":66,"type":20},"2028-12-01",{"name":68,"class":40},"Celgene",43,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":82,"conditions":83,"keywords":92,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100607438","phase-3-a-study-to-investigate-ronde-cel-versus-investigators-choice-cd19-car-t-cell-therapy-100607438","NCT07188558","A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19\u002FCD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting","PiNACLE-H2H","Key Inclusion Criteria:\n\n1. CAR T cell naïve and eligible to receive a CD19 CART-cell therapy\n2. Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)\n\n   * Diffuse large B-cell lymphoma (DLBCL)\n   * Transformations of indolent B-cell lymphomas (excluding Richter's transformation)\n   * DLBCL\u002FHigh-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements\n   * High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)\n   * Primary mediastinal large B-cell lymphoma (PMBCL)\n   * Grade 3B follicular lymphoma\u002Flarge cell follicular lymphoma (FL3B)\n3. Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy\n4. Measurable disease by presence of \\[18F\\]-fluorodeoxyglucose PET\u002FCT positive lesion during Screening per Lugano Criteria\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n6. Adequate hematological, renal, hepatic, pulmonary, and cardiac function\n\nKey Exclusion Criteria:\n\n1. Patients ineligible to receive CD19 CAR T-cell therapy\n2. Primary CNS lymphoma\n3. Patients with primary cutaneous LBCL, human herpes virus-8 positive lymphoma, Burkitt lymphoma, T cell histiocyte-rich lymphoma, or transformation from chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (Richter's transformation)\n4. Patients with prior history of malignancy, other than aggressive relapsed or refractory LBCL, unless the patient has been free of the disease for ≥ 2 years\n5. Patients with uncontrolled systemic fungal, bacterial, viral, or other infection (including tuberculosis) despite appropriate antibiotics or other treatment\n6. Active autoimmune disease requiring ongoing systemic immunosuppressive therapy.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply",{"count":79,"type":20},400,[81],"PHASE3","This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19\u002FCD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.",[84,27,85,86,87,88,89,90,91],"Large B-cell Lymphoma","Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Non-Hodgkin Lymphoma Refractory\u002F Relapsed","Diffuse Large B Cell Lymphoma (DLBCL)","Diffuse Large B Cell Lymphoma Refractory","Diffuse Large B Cell Lymphoma Relapsed",[93,87,94,95,96,84],"Lymphoma","CAR T-Cell Therapy","CD19","CD19\u002FCD20","2026-06-04",{"date":62,"type":33},{"date":100,"type":33},"2026-01-12",{"date":102,"type":20},"2032-01",{"name":104,"class":40},"Lyell Immunopharma, Inc.",38,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100471652","phase-1-a-study-of-jnj-90014496-in-participants-with-b-cell-non-hodgkin-lymphoma-100471652","NCT05421663","A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","A Phase 1b\u002F2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19\u002FCD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Participant must be greater than or equal to (\\>=) 18 years of age, at the time of signing informed consent\n* Tumor must be histologically confirmed cluster of differentiation (CD)19 and\u002For CD20 positive\n* Must meet the indications for each subtype in Phase 1b as specified in protocol and Phase 2 participants must have following: Diagnosis of Large B-cell lymphoma (LBCL), Follicular large B-cell lymphoma (FLBCL), or transformation of indolent lymphoma; Received at least 2 prior lines of systemic therapy; Relapsed or refractory disease defined as 1 or more of the following: Stable disease or Progressive disease (PD) as best response to most recent anti-lymphoma therapy OR disease progression or recurrence after a partial response (PR) or complete response (CR) to most recent anti lymphoma therapy; cohort specific requirements as mentioned in protocol\n* Measurable disease as defined by Lugano 2014 classification\n* Eastern cooperative oncology group (ECOG) performance status of 0 to 2\n\nExclusion Criteria:\n\n* History of symptomatic deep vein thrombosis or pulmonary embolism within six months of apheresis (line associated deep vein thrombosis is allowed)\n* History of stroke, unstable angina, myocardial infarction, congestive heart failure New York Heart Association (NYHA) Class III or IV, severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of apheresis\n* History of a seizure disorder, dementia, cerebellar disease or neurodegenerative disorder\n* Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system\n* Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)\n* Evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection\n* Diagnosis of Human herpes virus (HHV) 8-positive DLBCL or T cell\u002Fhistiocyte-rich large B-cell lymphoma or Burkitt and high-grade B-cell lymphoma with 11q aberrations (previously Burkitt-like lymphoma) or Richter's transformation or Lymphomatoid granulomatosis or Plasmablastic lymphoma or Waldenstrom's Macroglobulinemia\n* Any prior solid organ or allogeneic stem cell transplantation\n* Autologous stem cell transplant within 12 weeks of apheresis; Prior CAR-T cell therapy within 12 weeks of apheresis",{"count":114,"type":20},439,[23,24],"This is a Phase 1b\u002F2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r\u002Fr) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).",[118,27,119],"Lymphoma, Non-Hodgkin","Lymphoma, Large B-Cell, Diffuse",[121],"CD20\u002FCD19",{"date":60,"type":33},{"date":124,"type":33},"2022-08-12",{"date":126,"type":20},"2041-07-30",{"name":128,"class":40},"Janssen Research & Development, LLC",32,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100556684","phase-1-a-phase-1-study-of-ub-vv111-with-and-without-rapamycin-in-relapsedrefractory-cd19-b-cell-malignancies-100556684","NCT06528301","A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed\u002FRefractory CD19+ B-cell Malignancies","A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed\u002FRefractory (R\u002FR) CD19+ B-cell Malignancies","Inclusion Criteria:\n\n1. 18 years or older\n2. Provides voluntary written informed consent\n3. Relapsed or refractory large B-cell lymphoma (LBCL) or chronic lymphocytic leukemia (CLL)\n4. Measurable disease according to Lugano 2014 criteria (LBCL) or iwCLL 2018 (CLL).\n5. No serious concomitant diseases or active\u002Funcontrolled infections\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n7. Adequate organ function\n8. Patients who have previously received CD19-directed therapy must have biopsy confirming CD19 expression following completion of prior CD19-directed therapy.\n\nExclusion Criteria:\n\n1. Women who are pregnant or breastfeeding\n2. Current isolated central nervous system (CNS) involvement\n3. Prior allogeneic bone marrow transplant, gene therapy, or adoptive cell transfer (exceptions include tumor-infiltrating lymphocytes and CAR T cells)\n4. History of or active human immunodeficiency virus (HIV)\n5. Active hepatitis B or C\n6. Systemic immunodeficiency diseases, except for well-controlled Type I diabetes or thyroid disease\n7. Ongoing CNS disease that would preclude neurologic assessment\n8. Uncontrolled angina or other acute heart disease\n9. Currently receiving treatment in another interventional clinical trial.",{"count":138,"type":20},106,[23],"This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed\u002Frefractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).",[27,142,143,144],"Lymphoma, Non-Hodgkin (NHL)","Lymphoma, Large B-Cell, Diffuse (DLBCL)","Chronic Lymphocytic Leukemia (CLL)",[146,95,147],"CAR T","chimeric antigen receptor","2026-05-26",{"date":150,"type":33},"2026-05-28",{"date":152,"type":33},"2025-03-10",{"date":154,"type":20},"2029-03",{"name":156,"class":40},"Umoja Biopharma",8,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":184},"100589468","phase-2-defining-ctdna-metrics-in-posttransplant-lymphoproliferative-disorder-ptld-100589468","NCT06954805","Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)","Defining the Role of ctDNA Monitoring in a Risk Stratified Clinical Trial for Posttransplant Lymphoproliferative Disorder (PTLD)","Inclusion Criteria:\n\n* Histologically confirmed CD20+ PTLD including the below subtypes:\n\n  * Polymorphic\n  * Monomorphic\n* Age ≥ 15.\n* Participants must have measurable disease, defined as lymph node ≥ 1.5 cm in greatest diameter per Lugano Classification\n* Patients must have a PET-CT scan (preferred; alternatively CT chest, abdomen and pelvis with IV contrast) performed within 28 days prior to the start of the study.\n* All participants must be screened for chronic hepatitis B virus (HBV) within 28 days prior to registration. Participants with known HBV infection (positive serology) must also have a HBV viral load performed within 28 days prior to registration, and participants must have an undetectable HBV viral load on suppressive therapy within 28 days prior to start of treatment. Participants found to be HBV carriers during screening are eligible and must receive standard of care prophylaxis. Participants with active Hepatitis B (HBV viral load \\> 500 IU\u002FmL) within 28 days prior to registration are not eligible.\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with an active HCV infection who are currently on treatment must have an undetectable HCV viral load within 28 days prior to registration.\n* Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test (must be within 26 weeks prior to registration). Participants with known HIV must have a CD4 count checked within 28 days prior to registration, but may proceed with therapy regardless of CD4 count.\n* Organ function as assessed by laboratory testing is in appropriate range for receipt of rituximab and R-EPOCH per individual treating physician discretion.\n* Cardiac function testing is in appropriate range for receipt of rituximab and R-EPOCH per individual treating physician discretion.\n* Eastern Cooperate Oncology Group (ECOG) performance status is in appropriate range for receipt of rituximab and R-EPOCH per individual treating physician discretion.\n* Ability to understand and the willingness to sign a written informed consent document. In cases of partial impairment, impairment that fluctuates over time, or complete impairment due to dementia, stroke, traumatic brain injury, developmental disorders (including mentally disabled persons), serious mental illness, and delirium, a subject may be enrolled if the subject's legally authorized representative consents on the subject's behalf.\n* Due to the potential teratogenic effects of chemotherapy, women of childbearing age must have a documented negative serum β-hCG measured within 2 weeks of starting treatment.\n* Both women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence).\n* Women must agree to not breastfeed during the entirety of the study period.\n* Participants must not have had chemotherapy for other indications within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study and must have recovered from adverse events due to agents administered more than 4 weeks earlier.\n* Participants must not have received more than a cumulative of dose 250 mg\u002Fm 2 of prior doxorubicin (or equivalent dose of another anthracycline, such as epirubicin) therapy (at any time prior to registration).\n* Intrathecal chemotherapy administered for CNS prophylaxis is allowed in addition to protocol therapy per institution practice.\n\nExclusion Criteria:\n\n* Patients who have received systemic chemotherapy for PTLD.\n* Patients who have known lymphomatous involvement of the central nervous system (CNS).","15 Years",{"count":167,"type":20},30,[24],"The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in participants who have high-risk B-cell PTLD in their 2nd phase of treatment (consolidation) while those with low-risk disease will be spared of chemotherapy and treated with rituximab consolidation alone.\n\nThis study is also being done to find out about the usefulness of circulating tumor DNA (ctDNA), a novel blood test which, has been shown to help guide treatment decisions in other types of lymphoma. The goal is to answer the question if ctDNA is a viable and informative tool in treating PTLD with the hope that in the future it may be used to individualize study treatment for participants with PTLD in a way that limits study treatment toxicity without losing the effectiveness of the treatment plan.",[93,27],[172,173],"posttransplant","lymphoproliferative disorder","2026-05-22",{"date":176,"type":33},"2026-05-27",{"date":178,"type":33},"2025-04-14",{"date":180,"type":20},"2028-04-14",{"name":182,"class":183},"Jennifer Amengual","OTHER",2,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":192,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":196,"conditions":197,"keywords":202,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":215},"100385614","study-of-car-t-therapy-in-older-patients-100385614","NCT04300998","Study of CAR-T Therapy in Older Patients","Observational Study of Commercial Chimeric Antigen Receptor T-cell (CAR T) Therapy in Older Patients With Hematologic Malignancies and With an Embedded Pilot Study of Longitudinal Geriatric and Neurocognitive Evaluation","Inclusion Criteria:\n\n* are ≥60 years old (all cohorts)\n* have pathologically confirmed, relapsed refractory lymphoid malignancy or plasma cell disorder receiving a commercial CAR T-cell product (all cohorts)\n* able to speak and understand English (cohort 1 and 4 only)\n* have a MoCA score of less than 26 out of 30 during the GA visit by a geriatrician prior to CAR T-cell treatment (cohort 4 only)\n\nExclusion Criteria:\n\n* Any prior commercial or investigational CAR T therapy (all cohorts)\n* Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report (cohort 1 only)\n* History of a neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness (\\>60 minutes), as per medical records or patient report (cohort 1 only)\n* Current ongoing substance abuse and\u002For history of substance abuse, as per medical records or patient report (cohort 1 only)\n* History of CNS disease (cohort 4 only)","60 Years",{"count":194,"type":20},154,"OBSERVATIONAL","This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' disease.",[93,198,27,199,200,201],"Refractory B-Cell Lymphoma","DLBCL NOS","High-grade B-cell Lymphoma","Multiple Myeloma",[93,203,204,200,199,198,205,206],"CART therapy","relapsed refractory large B-cell lymphoma","19-452","Memorial Sloan Kettering Cancer Center","2026-04-01",{"date":209,"type":33},"2026-04-07",{"date":211,"type":33},"2020-03-04",{"date":213,"type":20},"2027-03-04",{"name":206,"class":183},1,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":21,"phases":225,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":215},"100631606","phase-2-tpg-tafasitamab-polatuzumab-vedotin-and-glofitamab-as-first-line-therapy-for-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma-100631606","NCT07502872","TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma","TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma","TPG","Inclusion Criteria:\n\n1. Ability to understand and the willingness to sign a written informed consent document and to comply with the study protocol procedures.\n2. Age ≥18 years.\n3. Histologically confirmed diagnosis of DLBCL, or HGBL, according to 5th edition WHO classification. Eligible WHO entities include:\n\n   * Diffuse large B-cell lymphoma, not otherwise specified (NOS)\n   * T-cell\u002Fhistiocyte-rich large B-cell lymphoma\n   * DLBCL\u002FHGBL with MYC and BCL2 rearrangements\n   * Large B-cell lymphoma with IRF4 rearrangement\n   * HGBL with 11q aberration\n   * EBV-positive diffuse large B-cell lymphoma\n   * DLBCL associated with chronic inflammation\n   * Primary large B-cell lymphoma of immune-privileged sites\n   * Primary cutaneous DLBCL, leg type\n   * Intravascular large B-cell lymphoma\n   * Primary mediastinal large B-cell lymphoma\n   * HGBL, NOS\n   * Grade 3B follicular lymphoma.\n4. FDG-avid disease by PET-CT Lugano criteria.\n5. No prior systemic therapy for B-cell lymphoma, except for:\n\n   * corticosteroids;\n   * a single cycle of chemotherapy administered prior to enrollment (to facilitate enrolling patients who require emergent initiation of therapy for rapidly progressive or symptomatic lymphoma);\n   * prior local radiation therapy;\n   * prior treatment for indolent lymphoma.\n6. Performance status ECOG 0, 1, or 2.\n7. Ability to receive one of the standard chemotherapy regimens for DLBCL\u002FHGBL including attenuated versions, where clinically appropriate\n8. Required initial laboratory values: (unless due to underlying lymphoma):\n\n   * absolute neutrophil count ≥1.0 x 109\u002FL,\n   * platelet count ≥75 x 109\u002FL.\n   * creatinine ≤ 1.5 mg\u002FdL or glomerular filtration rate (GFR) ≥40 mL\u002Fmin\u002F1.73m2 using the Mayo Quadratic Formula\n   * total bilirubin ≤ 1.5 × institution upper limit of normal (ULN) unless attributable to Gilbert's disease\n   * AST and ALT ≤ 3 × institution ULN.\n   * Negative antigen or PCR test for SARS-CoV-2.\n9. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) and refrain from donating eggs or sperm throughout the treatment and for 3 months after the last dose of trial therapy.\n\nExclusion Criteria:\n\n1. Pregnancy, breast-feeding, or prisoner status.\n2. Central nervous system involvement by the lymphoma.\n3. Prior solid organ transplantation or allogeneic stem cell transplantation.\n4. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products.\n5. Known NYHA class 3\u002F4 congestive heart failure, left ventricular ejection fraction (LVEF) \\\u003C30%, or active ischemic heart disease.\n6. Chronic obstructive pulmonary disease (COPD) requiring continuous oral corticosteroids or chronic oxygen.\n7. Grade \\>1 peripheral neuropathy.\n8. Use of systemic immunosuppressive medications (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents), within 2 weeks prior to first dose of study treatment (except as allowed in the inclusion criteria for the management of lymphoma).\n9. Any of the following conditions:\n\n   * active bacterial infection requiring antibiotics\n   * chronic active Epstein Barr virus (CAEBV) infection\n   * history of hemophagocytic lymphohistiocytosis (HLH)\n   * history of Stevens-Johnson syndrome or toxic epidermal necrolysis\n   * progressive multifocal leukoencephalopathy (PML)\n   * known active EBV or CMV viremia\n   * autoimmune disease requiring systemic immunosuppressive therapy\n   * active myasthenia gravis, myositis, autoimmune hepatitis, idiopathic pulmonary fibrosis, systemic lupus erythematosus, inflammatory bowel disease, granulomatosis with polyangiitis, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis\n   * active hepatitis B (HBV) or hepatitis C (HCV) infection. Patients with a positive total\u002FIgG HBV core antibody (HBcAb) are eligible if (1) HBV DNA is documented at screening, (2) they agree to take entecavir or tenofovir, and (3) they agree to undergo periodic DNA testing. Patients with a positive HCV antibody are eligible if a negative polymerase chain reaction (PCR) for HCV is documented.\n   * HIV infection with a detectable viral load or a CD4 count \\\u003C200 cells\u002Fmm3. Patients (1) with an undetectable viral load and CD4 count \\>200 cells\u002Fmm3 within 6 months prior to enrollment, and (2) on antiretroviral therapy are eligible.\n10. Administration of a live, attenuated vaccine within 4 weeks before first treatment or anticipation that such a live, attenuated vaccine will be required during the study.\n11. History of other malignancy that could affect compliance with the protocol or interpretation of the primary endpoint in the judgement of the investigator.\n12. Any major surgery within 4 weeks before the first dose of treatment.\n13. Evidence of other significant or uncontrolled medical or psychiatric conditions that could affect compliance with the protocol, in the judgement of the investigator.",{"count":167,"type":20},[24],"This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).",[228,200,93,27],"Diffuse Large B Cell Lymphoma",[230,231,232,233],"glofitamab","polatuzumab vedotin","tafasitamab","immunotherapy","NOT_YET_RECRUITING","2026-03-25",{"date":237,"type":33},"2026-03-31",{"date":239,"type":20},"2026-05-01",{"date":241,"type":20},"2029-12-01",{"name":243,"class":183},"Brown University",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":21,"phases":253,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":215},"100569406","ctdna-guided-therapy-optimization-in-newly-diagnosed-dlbcl-100569406","NCT06693830","ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL","Sequencing-guided cHemotherapy Optimization Using Real-Time Evaluation in Newly Diagnosed DLBCL With Circulating Tumor DNA: SHORTEN-ctDNA","Inclusion Criteria:\n\n1. Patients with newly diagnosed, histologically confirmed CD20+ DLBCL\n\n   * Stage II-IV disease\n   * Planned for anthracycline-based therapy with standard dosed R-CHOP or R-pola- CHP without consolidative radiation\n   * Measurable disease on cross sectional imaging ≥ 1.5 cm in longest diameter and measurable in two perpendicular dimensions, with at least one corresponding hypermetabolic lesion by Lugano classification on baseline FDG PET\u002FCT or CT with intravenous contrast of the chest, abdomen, and pelvis if FDG PET\u002FCT not available.\n2. Age 18 years or older at time of screening\n3. Subject\u002Flegal representative willing and able to provide written informed consent\n4. Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for duration of study participation\n5. Organ function as assessed by laboratory and cardiac function testing and Eastern Cooperative Oncology Group (ECOG) performance status in appropriate range for receipt of R-CHOP or R-pola-CHP at standard dose as per treating physician\n\nExclusion Criteria:\n\n1. Previous treatment for diffuse large B-cell lymphoma, except as outlined below:\n\n   * Up to 14 days of corticosteroids for the relief of lymphoma-related symptoms\n   * A dose of pre-phase vincristine or rituximab\n   * One cycle of R-chemotherapy (including but not limited to R-CHOP, R-pola-CHP, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab \\[DA-EPOCH-R) that has not started more than 28 days prior to consent\n   * Intrathecal chemotherapy for central nervous system (CNS) prophylaxis\n   * Radiation therapy for the treatment or prevention of spinal cord compression that has not started more than 28 days prior to enrollment\n2. Simultaneous participation in other treatment clinical protocol\n3. Planned anti-lymphoma therapies beyond R-CHOP or R-pola-CHP:\n\n   * Consolidative radiation to any baseline sites of disease\n   * Planned high-dose intravenous methotrexate for central nervous system (CNS) lymphoma prophylaxis (both mid-cycle and EOT excluded)\n\n     * Any number of doses of intrathecal chemotherapy for CNS lymphoma prophylaxis are allowed\n4. Transformed indolent lymphoma (including follicular lymphoma, marginal zone lymphoma, or lymphoplasmacytic lymphoma) or grade IIIB follicular lymphoma\n5. Known CNS involvement by lymphoma. R-CHOP and R-pola- CHP are insufficient to treat CNS disease.\n6. Any disease characteristics that would make R-CHOP or R-pola-CHP without radiation insufficient therapy at the discretion of the treating physician\n\n   * High-grade B-cell lymphoma with rearrangement of MYC and BCL2, primary mediastinal B-cell lymphoma, and HIV-associated lymphomas are excluded\n7. Richter transformation of chronic lymphocytic leukemia\n8. Pregnancy and\u002For nursing period. R-CHOP and R-pola-CHP may cause fetal harm or birth defects, and effects of exposure in the breastfed infant are unknown.\n\n   * A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of \"childbearing potential\"\n   * Women of childbearing potential are eligible if a negative serum or urine beta human chorionic gonadotropin pregnancy test is documented within 28 days of screening, and they must agree to us an effective contraception method during systemic treatment\n   * Men who have partners of childbearing potential must agree to use an effective contraceptive method during systemic treatment\n   * In addition to routine contraceptive methods, \"acceptable contraception\" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation\u002Focclusion, and vasectomy with testing showing no sperm in the semen.\n9. Uncontrolled active systemic infection\n\n   * Patients with a positive hepatitis B virus (HBV) core antibody and negative HBV surface antigen consistent with prior HBV exposure must be willing to take appropriate anti-viral prophylaxis.\n   * Patients with evidence of chronic HBV infection must have undetectable HBV viral load on the most recent test results obtained within the last year and received suppressive therapy.\n   * Participants with a history of hepatitis C virus (HCV) infection must have an undetectable viral load. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 28 days prior to consent.\n10. Active second malignancy unless in remission and with life expectancy \\> 2 years with exception of patients diagnosed with basal cell or squamous cell carcinoma of the skin or carcinoma \"in situ\" of the cervix or breast who are eligible even if diagnosed within 2 years. If patients have another malignancy that was treated within the last 2 years, such patients may be enrolled, if the likelihood of requiring systemic therapy for this other malignancy within 2 years is less than 10%, as determined by an expert in that particular malignancy at CUIMC, and after consultation with the Principal Investigator. Hormone therapy for treated prostate and breast cancer is allowed.\n11. Known hypersensitivity to any component of R-CHOP or R-pola-CHP",{"count":252,"type":20},40,[254],"NA","The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL), and 2) evaluate the outcomes of participants with undetectable ctDNA in the middle of treatment who receive a shortened course of chemotherapy.\n\nThere are no investigational drug agents to be administered in this study. The investigational assay, phased variant enrichment and detection sequencing (PhasED-seq) will be used to guide de-escalation of standard-of-care therapy for newly diagnosed DLBCL.\n\nThe PhasED-seq assay has not yet been approved by the Food and Drug Administration (FDA).",[93,27,228,257,200],"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",[259,260],"circulating tumor DNA","measurable residual disease","2026-01-22",{"date":263,"type":33},"2026-01-23",{"date":265,"type":33},"2024-12-11",{"date":267,"type":20},"2029-12",{"name":269,"class":183},"Hua-Jay J Cherng, MD",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":278,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":21,"phases":281,"briefSummary":282,"conditions":283,"keywords":290,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":215},"100553360","early-palliative-care-for-patients-with-multiple-myeloma-and-aggressive-lymphoma-100553360","NCT06485076","Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma","Phase II Feasibility Study of Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma","EPC-MM+L","Patient eligibility criteria:\n\nInclusion criteria:\n\n(i) Age ≥18 years; (ii) A new diagnosis of multiple myeloma or at progression of disease necessitating a change in treatment plan, or relapsed\u002Frefractory aggressive B cell lymphoma after one prior line of therapy; (iii) Eastern Cooperative Oncology Group (ECOG) performance status 0-3; (iv) Willingness to complete symptom screening; and (v) At least one ESAS-r-plus symptom scored at ≥3 at time of recruitment.\n\nExclusion criteria:\n\n(i) Insufficient English literacy to complete study procedures; (ii) Hematologist-determined poor cognitive status; (iii) Current palliative care team involvement at PM or elsewhere; and (iv) Not receiving ongoing follow up with malignant hematology team at PM.\n\nCaregiver eligibility criteria:\n\nInclusion criteria:\n\n(i) Age ≥18 years; (ii) Caregiver of a patient with relapsed B cell lymphoma; and (iii) Willing to attend at least 1 PCC visit with the patient.\n\nExclusion criteria:\n\n(i) Insufficient verbal and\u002For written English literacy to complete study procedures; or (ii) Patient not participating in study.\n\nHealthcare provider eligibility criteria:\n\nInclusion criteria:\n\n(i) Specialized staff physician, fellow, clinical nurse specialist, or clinic nurse from the outpatient malignant hematology team or palliative care team at PM working clinically with patients with multiple myeloma; and (ii) Working in their clinical area for at least 12 months.",true,{"count":280,"type":20},144,[254],"Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in goals of care conversations occurring late in the illness trajectory and aggressive care being received in the last 30 days of life. Early palliative care alongside usual cancer care has been shown to improve patient outcomes such as symptom burden, mood, and quality of life in patients with solid tumours (e.g. lung, breast or gynecological cancers), but has not been explored among patients with blood cancers to date.\n\nThe goal of this clinical trial is to a brief early palliative care intervention for patients with multiple myeloma and aggressive B cell lymphoma and their caregivers (lymphoma only) attending the Princess Margaret Cancer Centre. The main goals of the study are:\n\n* To see if it is possible to apply the early palliative care intervention for patients with multiple myeloma and aggressive lymphoma and their caregivers (lymphoma only)\n* To see if this early palliative care intervention works well for these patients and caregivers\n* To compare patient and caregiver experiences with early palliative care and usual care\n* To explore perceptions and experiences of providing palliative care among healthcare providers involved in the care of these patients and caregivers.\n\nPatients, and their respective caregivers if participating, will be randomly assigned to one of two groups: one group will receive early palliative care in addition to usual care from their blood cancer doctor, and the other group will receive usual care from their blood cancer doctor only. All participants will be asked to fill out questionnaires about their quality of life, symptom burden, mood, and satisfaction with care throughout the study. Researchers will compare the results between the two groups to see if there are any improvements in quality of life for the patients who received early palliative care and their caregivers.\n\nSome patients and caregivers will be asked to take part in interviews at the end of the trial to answer questions about their experience taking part in the study. Some healthcare providers who care for these patients will also be asked to take part in interviews at the end of the trial to describe their perceptions and experiences of providing palliative care.\n\nThe researchers will use the results of this study to guide in the development of a larger clinical trial.",[284,285,286,287,201,288,27,289],"Multiple Myeloma in Relapse","Multiple Myeloma, Refractory","Multiple Myeloma Stage III","Multiple Myeloma Progression","B Cell Lymphoma","Aggressive Lymphoma",[291,292,293,294,295],"early palliative care","multiple myeloma","quality of life","symptom management","aggressive lymphoma","2025-11-25",{"date":298,"type":33},"2025-12-03",{"date":300,"type":33},"2024-07-18",{"date":302,"type":20},"2027-06",{"name":304,"class":183},"University Health Network, Toronto",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":278,"sex":16,"minAge":17,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":215},"100104689","family-study-of-lymphoproliferative-disorders-100104689","NCT00626496","Family Study of Lymphoproliferative Disorders","Genetic Epidemiology of Lymphoproliferative Disorders","At least 2 living, blood related relatives, affected with a lymphoproliferative disorder.","100 Years",{"count":314,"type":20},3000,"Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic leukemia and non-Hodgkin lymphoma. Since there is evidence that these cancers cluster in families, this study aims to understand how genetics and environmental exposures contribute to the development of these cancers.",[118,317,27,318,201],"Leukemia, Lymphocytic, Chronic, B-Cell","Monoclonal B-Cell Lymphocytosis","2025-10-09",{"date":321,"type":33},"2025-10-14",{"date":323,"type":33},"2004-04-01",{"date":325,"type":20},"2029-12-31",{"name":327,"class":183},"Mayo Clinic",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":21,"phases":337,"briefSummary":338,"conditions":339,"keywords":343,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":184},"100511502","study-of-a-communication-training-intervention-for-large-b-cell-lymphoma-providers-100511502","NCT05940272","Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers","Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers","Inclusion Criteria:\n\nProviders\n\n* Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)\n\nPatients\n\n* Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, \"treating provider\" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)\n* Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma\n* Per medical record, relapse\u002F refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT)\n* Self-identify as Black and\u002For White\n* Per medical record, 18 years of age or older\n* Per self-report, fluent in English\\*\\*\n\n  * Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:\n\n    1. How well do you speak English? (must respond \"very well\" or \"well\" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)\n    2. What is your preferred language for healthcare? (must respond English)\n\nExclusion Criteria:\n\nProviders\n\n* Per self-report, planning to leave the cancer center in the next 12 months\n\nPatients\n\n* Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11\n* Per research staff judgment and\u002For self-report, too ill or weak to complete study procedures\n* Per medical record or self-report, receiving hospice care at the time of enrollment",{"count":336,"type":20},48,[254],"The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.",[27,93,340,84,341,342],"Large-cell Lymphoma","DLBCL - Diffuse Large B Cell Lymphoma","Mediastinal B-Cell Diffuse Large Cell Lymphoma",[344,345,346,347,348,349,228,342,350,351,206],"oncologist","hemotologic oncologist","lymphoma","large cell lymphoma","large b-cell lymphoma","DLBCL","Hematolo-GIST","23-164","2025-10-08",{"date":319,"type":33},{"date":355,"type":33},"2023-07-03",{"date":357,"type":20},"2028-07-03",{"name":206,"class":183},{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":21,"phases":368,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":215},"100577010","phase-1-phase-1-trial-of-btm-3566-in-relapsedrefractory-mature-b-cell-lymphomas-100577010","NCT06792734","Phase 1 Trial of BTM-3566 in Relapsed\u002FRefractory Mature B Cell Lymphomas","Phase 1A\u002F1B Trial of BTM-3566 in Relapsed\u002FRefractory Mature B Cell Lymphomas","Inclusion Criteria:\n\n* must be age ≥18 years\n* must have a diagnosis of relapsed or refractory mature B cell lymphoma\n* must have measurable disease per response evaluation criteria in lymphoma (Lugano classification)\n* must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2\n* must have a predicted life expectancy of ≥3 months\n* must agree to use adequate birth control throughout their participation and for 90 days following the last dose of BTM-3566\n\nExclusion Criteria:\n\n* has primary CNS lymphoma\n* has ongoing toxicities from prior anti-cancer treatment \\> Grade 1\n* has symptomatic or uncontrolled neurologic disease (brain metastases, leptomeningeal disease, or spinal cord compression) not definitively treated with surgery or radiation\n* has received any anti-cancer therapy (including radiation of curative intent) \\\u003C28 days prior to administration of BTM-3566\n* has current second malignancy at other sites (exceptions: non-melanomatous skin cancer, adequately treated in situ carcinoma, or indolent prostate cancer under observation).\n* is pregnant or breastfeeding",{"count":367,"type":20},24,[23],"The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also learn how well BTM-3566 works to treat relapsed or refractory mature b cell lymphomas. The main questions it aims to answer are:\n\nWhat are the side effects of BTM-3566 at different doses? What are the levels of BTM-3566 in the blood at different timepoints around dosing? What is the clinical benefit of BTM-3566 in treating cancer (i.e. how well does it slow or stop disease progression)?\n\nParticipants will:\n\nTake BTM-3566 in 14-day periods with 7 days of dosing followed by 7 days of no dosing Visit the clinic regularly for checkups and tests Keep a diary of their dosing and weight",[27],"2025-09-15",{"date":373,"type":33},"2025-09-18",{"date":375,"type":33},"2025-02-14",{"date":377,"type":20},"2027-12",{"name":379,"class":40},"Bantam Pharmaceuticals",{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":389,"conditions":390,"keywords":394,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":215},"100543063","early-assessment-of-cardiac-function-after-treatment-with-car-t-cells-100543063","NCT06350994","Early Assessment of Cardiac Function After Treatment With CAR-T Cells","Cardio CAR-T","Inclusion Criteria:\n\n* CAR-T cells infusion received within 3 to 5 days before the echocardiography\n* Pre-therapeutic cardiac assessment (in accordance with the recommendations and standard care protocol in force in the hematology department of Saint-Antoine Hospital): Echocardiography and EKG before conditioning and infusion of CAR -T cells,\n* Not opposed to participating in research.\n* Patient affiliated to a social security system or beneficiary of the \"state medical insurance help\" (namely aide médicale d'état).\n\nExclusion Criteria:\n\n* Opposition or consent withdrawal",{"count":388,"type":20},60,"CAR-T cells (Chimeric Antigen Receptor) are a new immunotherapy, based on the genetic modification of autologous T lymphocytes. CAR-T cell therapy is not devoid of complications.\n\nAmong the most frequent complications are the risk of infection, cytokine release syndrome (CRS) and neurotoxicity. Nevertheless, some authors have reported serious acute cardiac events in a limited number of patients, often contemporaneous with CRS or sepsis, questioning the imputability of CAR-T cells in this heart disease.\n\nThis study aims to estimate the incidence of a possible early cardiotoxicity associated with CAR-T cells.\n\nThe main endpoint will be the change in cardiac function (LVEF: left ventricular ejection fraction) assessed by ultrasound between the pre CAR-T assessment and the early post CAR-T ultrasound (D3-D5).",[391,392,393,27,201],"Car T- Cell","Hematologic Malignancy","Acute Lymphoblastic Leukemia",[395,396,397,398,399],"CAR-T cells","Hematological malignancies","Cardiomyopathy","Cardiotoxicity","Pharmacovigilance","2025-08-29",{"date":402,"type":33},"2025-09-02",{"date":404,"type":33},"2024-11-07",{"date":406,"type":20},"2027-03",{"name":408,"class":183},"Assistance Publique - Hôpitaux de Paris",{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":215},"100534661","prospective-observational-study-of-diffuse-large-cell-b-lymphoma-100534661","NCT06241729","Prospective Observational Study of Diffuse Large-cell B Lymphoma","Supervised Machine Learning for the Prediction of Primary Refractory Status in Patients With Diffuse Large Cell B Lymphoma in a Monocentric Cohort at the Grand Hôpital de Charleroi","LBDGCréfract","Inclusion Criteria:\n\n* patients with diffuse large-cell B lymphoma treated in the haematology department at the Grand Hôpital de Charleroi for the first time\n* able to understand the information and sign their consent form\n\nExclusion Criteria:\n\n* under 18 years old",{"count":418,"type":20},50,"Diffuse large B-cell lymphoma (DLBCL) represents the most common type of non-Hodgkin lymphoma and is currently a curable malignant disease for many patients with immuno-chemotherapy frontline treatment. However, around 30-40 % of patients, are unresponsive or will experience early relapse. The prognosis of primary refractory patient is poor and the management and treatment are a significant challenge due to the disease heterogeneity and the complex genetic framework. The reasons for refractoriness are various and include genetic abnormalities, alterations in tumor and tumor microenvironment. Patient related factors such as comorbidities can also influence treatment outcome. Recently the progress in Machine learning (ML) showed its usefulness in the procedures used to analyze large and complex datasets. In medicine, machine learning is used to create some predictive tools based on data-driven analytic approach and integration of various risk factors and parameters. Machine learning, as a subdomain of artificial intelligence (AI), has the capability to autonomously uncover patterns within datasets. It offers algorithms that can learn from examples to perform a task automatically.The investigators tested in a previous study five machine learning algorithms to establish a model for predicting the risk of primary refractory DLBCL using parameters obtained from a monocentric dataset. The investigators observed that NB Categorical classifier was the best alternative for building a model in order to predict primary refractory disease in DLBCL patients and the second was XGBoost.The investigators plan to extend this previous study by further exploring the two best-performing models (NBC Classifier and XGBoost), progressively incorporating a larger number of patients in a prospective way.",[27],"2025-07-30",{"date":423,"type":33},"2025-07-31",{"date":425,"type":33},"2023-01-03",{"date":427,"type":20},"2026-12-31",{"name":429,"class":183},"Grand Hôpital de Charleroi",{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":11,"sex":16,"minAge":437,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":21,"phases":440,"briefSummary":441,"conditions":442,"keywords":445,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":460},"100519619","phase-1-a-phase-iii-trial-of-aleta-001-for-the-treatment-of-participants-with-b-cell-malignancies-100519619","NCT06045910","A Phase I\u002FII Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies","A Cancer Research UK Phase I\u002FII Trial of ALETA-001 in Participants Who Have Received an Anti-CD19 CAR T-Cell Therapy for the Treatment of B-cell Malignancies","Inclusion Criteria:\n\nFor all participants\n\nCriteria to be met prior to enrolment in the trial:\n\n* Aged 16 years or over.\n* Written (signed and dated) informed consent and be capable of co-operating with ALETA-001 administration and follow-up.\n* Confirmed diagnosis of B-cell NHL according to World Health Organization (WHO) 2016 criteria.\n* Eastern Cooperative Oncology Group performance status of 0, 1 or 2.\n* Biochemical indices within protocol specified ranges.\n\nCohort Specific Inclusion criteria (for Phase I Cohorts A \\& B) Criteria to be met prior to enrolment in the trial.\n\n* Histologically confirmed diagnosis of relapsed\u002Frefractory LBCL or MCL.\n* Have received an approved anti-CD19 CAR T-cell therapy.\n* Objectively evaluable or measurable disease at 4 weeks (±1 week) post CAR T, which demonstrates:\n\n  * inadequate or incomplete response (PR or SD), or\n  * PD if there is a reasonable expectation of deriving benefit from trial treatment, or\n  * initial response followed by relapse within 9 months assessed according to Lugano Criteria.\n* Haematological indices within protocol specified ranges.\n\nCohort Specific Inclusion criteria (for Phase I Cohorts C \\& D) Criteria to be met prior to lymphodepleting chemotherapy for CAR T therapy.\n\n* Histologically confirmed diagnosis of relapsed\u002Frefractory LBCL or MCL.\n* Approved by the UK national CAR T Clinical Panel (NCCP) to receive an approved anti-CD19 CAR T-cell therapy.\n* Haematological indices within protocol specified ranges.\n* Adequate cardiac function within protocol specified ranges with no clinical symptoms or signs of heart failure.\n* Resting O2 saturation of ≥92% on room air.\n\nEligibility for participants in Phase II of the trial will depend on timing of administration of ALETA-001 which will be recommended by the Safety Review Committee (SRC).\n\nExclusion Criteria for all participants:\n\n* Active or previous malignancies of other types that, in the opinion of the Investigator, should exclude the participant. Exceptions include adequately treated cone biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin and patients with asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or who require only hormonal therapy and have had normal prostate specific antigen for \\>1 year prior to the start of therapy. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for 2 years or more and are deemed at negligible risk for recurrence, are eligible for the trial.\n* Any ongoing toxic manifestation of previous anti-cancer treatment that, in the opinion of the Investigator, should exclude the participant.\n* Ongoing need for systemic immunosuppressive therapy other than replacement dose of corticosteroids. Intermittent topical, inhaled or intranasal corticosteroids are permitted.\n* Presence of active infections and\u002F or inflammatory disease requiring active management.\n* Documented current central nervous system involvement by lymphoma.\n* Women of childbearing potential (or are already pregnant or lactating) unless willing to adhere to protocol-defined contraceptive requirements.\n* Male patients with partners of childbearing potential unless willing to adhere to protocol-defined contraceptive requirements.\n* Major thoracic or abdominal surgery from which the participant has not yet recovered.\n* At high medical risk because of non-malignant systemic disease including active uncontrolled infection.\n* Hypersensitivity to any of the ingredients\u002Fexcipients in ALETA-001.\n* Participation in another interventional clinical trial, whilst taking part in this trial of ALETA-001. Participation in an observational trial or interventional clinical trial that does not involve administration of an IMP and that would not place an unacceptable burden on the participant, in the opinion of the Investigator and CDD, would be acceptable.\n* Participants with any congenital or acquired immunodeficiency syndrome or who are receiving immunosuppressive therapy (including any dose of systemic corticosteroids), or who are immunosuppressed post organ transplant. However, participants receiving inhaled corticosteroids and participants with a history of allergy (other than anaphylaxis) are eligible, as are participants with a history of autoimmune disease.\n* Any other condition that, in the Investigator's opinion, would mean that the trial is not in the best interests of the participant.\n* Concurrent radiotherapy (except for palliative reasons).\n\nCohort specific exclusion criteria prior to enrolment in the trial (for Phase I\n\nCohorts A \\& B):\n\n* Participants who have received any other systemic anti-cancer treatment post-CAR T.\n* Potential participants who experienced any of the following because of the initial CAR T treatment:\n\n  * Grade 4 CRS or ICANS post CAR T infusion.\n  * Grade ≥3 CRS or ICANS persisting beyond 7 days despite optimal therapy.\n  * Any Grade ≥1 CRS or ICANS must have fully resolved.\n* Any Grade ≥3 organ toxicity (other than haematologic toxicity) following CAR T infusion must have improved to Grade ≤2 for at least 48 hours prior to ALETA-001 infusion.\n\nCohort specific exclusion criteria prior to ALETA-001 infusion between Day 10-18 post CAR T-cell infusion (for Phase I Cohorts C \\& D):\n\n* Grade 4 CRS or ICANS post CAR T infusion.\n* Grade ≥3 CRS or ICANS persisting beyond 7 days despite optimal therapy.\n* Any Grade ≥2 CRS or ICANS must have improved to Grade ≤1 for at least 48 hours prior to ALETA-001 infusion.\n* ECOG performance status ≥3.\n* Any Grade ≥3 organ toxicity (other than haematologic toxicity) following CAR T infusion must have improved to Grade ≤2 for at least 48 hours prior to ALETA-001 infusion.\n* Any unresolved serious active infection which in the opinion of the Investigator precludes ALETA-001 infusion (ongoing need for IV antimicrobial therapy per se is not an exclusion).","16 Years",{"count":439,"type":20},84,[23,24],"This is a Phase I\u002FII multicentre, open-label trial designed to evaluate the efficacy, safety, tolerability, timing of administration and pharmacokinetics (PK) of a novel chimeric antigen receptor (CAR) T-cell engager, ALETA-001, administered by intravenous (IV) infusion as a single agent every 2 weeks in participants with B-cell malignancies post CD19 CAR T-cell therapy. This first in human study is divided into 2 parts: a safety lead-in phase (Phase I) and a dose expansion phase (Phase II). Different dose levels of ALETA-001 and timing of administration will be evaluated in Phase I in order to define a recommended dosing level and time of administration for Phase II. Phase II will further evaluate the safety, PK and therapeutic activity of ALETA-001.",[118,119,443,444,27,84],"Lymphoma, Mantle-Cell","Lymphoma, Follicular",[446,447,448,449,450],"Neoplasms","Immunotherapy, Adoptive","Receptors, Chimeric Antigen","Receptors, Antigen, T-Cell","Antigens, CD19","2025-07-24",{"date":453,"type":33},"2025-07-28",{"date":455,"type":33},"2024-02-07",{"date":457,"type":20},"2029-12-21",{"name":459,"class":183},"Cancer Research UK",7,{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":4,"eligibilityCriteria":467,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":21,"phases":470,"briefSummary":471,"conditions":472,"keywords":473,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":215},"100394733","phase-1-retreatment-with-ctl019ctl119-100394733","NCT04419909","Retreatment With CTL019\u002FCTL119","Retreatment With CTL019\u002FCTL119 in Patients With Late Relapse of B-Cell Lymphomas","Inclusion Criteria:\n\n1. Diffuse Large B-Cell Lymphoma or Follicular lymphoma, previously identified as CD19+\n2. Previously treated on UPCC13413\u002F NCT02030834 with CTL019\u002FCTL119, with historical manufactured product available at Penn for reinfusion\n3. Previous complete response to CAR T-cells with a duration ≥ 6 months (defined as 168 days)\n4. No available curative treatment options (such as autologous or allogeneic HSCT) with limited prognosis (several months to \\\u003C 2 year survival) with currently available therapies.\n5. Age ≥18 years\n6. Creatinine \\\u003C 1.6 mg\u002FdL\n7. ALT\u002FAST \\\u003C 3x upper limit of normal\n8. Bilirubin \\\u003C 2.0 mg\u002FdL, unless subject has Gilbert's Syndrome (≤3.0 mg\u002FdL)\n9. Measurable or assessable disease according to the \"Revised Response Criteria for Malignant Lymphoma\" (Cheson et al., J. Clin. Onc., 2007)88. Patients in complete remission with no evidence of disease are not eligible.\n10. Performance status (ECOG) 0 or 1.\n11. Left Ventricle Ejection Fraction (LVEF) \\> 40% confirmed by ECHO\u002FMUGA\n12. Agree to contraceptive requirements outlined in Section 4.3.\n13. Provide written informed consent.\n\nExclusion Criteria:\n\n1. Uncontrolled active infection.\n2. Active hepatitis B or hepatitis C infection.\n3. Any uncontrolled active medical disorder that would preclude participation as outlined.\n4. Class III\u002FIV cardiovascular disability according to the New York Heart Association Classification (see Appendix 1).\n5. HIV infection.\n6. Patients with active CNS involvement by malignancy. Patients with prior CNS disease that has been effectively treated will be eligible providing treatment was \\>4 weeks before enrollment\n7. Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system.",{"count":469,"type":20},12,[23],"This research study is designed to evaluate the effects of retreatment with CTL019\u002FCTL119 in patients with late relapse of B-cell lymphomas.",[27],[474,475,476,477],"CTL019","CTL119","CAR T-cell","CART","2025-06-27",{"date":480,"type":33},"2025-07-02",{"date":482,"type":20},"2026-05",{"date":484,"type":20},"2028-07",{"name":486,"class":183},"University of Pennsylvania",{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":11,"sex":16,"minAge":494,"maxAge":495,"enrollmentInfo":496,"targetDuration":4,"studyType":21,"phases":498,"briefSummary":499,"conditions":500,"keywords":502,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":215},"100582712","cd-19-car-t-cell-for-pediatric-all-or-lymphoma-100582712","NCT06866873","CD-19 CAR-T Cell for Pediatric ALL or Lymphoma","Safety and Feasibility Study of CD19 Chimeric Antigen Receptor (CAR) T Cells in Children with Relapsed or Refractory CD19 Positive Acute Lymphoblastic Leukemia or Lymphoma","Inclusion Criteria:\n\n* Subjects must have relapsed or refractory ALL or lymphoma treated with at least two lines of therapy. Disease must have either progressed after the last regimen or presented failure to achieve partial or complete remission with the last regimen.\n* The patient's disease must be CD19 positive, either by immunohistochemistry or flow cytometry analysis on the last biopsy available.\n* Age 1-17 years.\n* Performance status: Subjects \\> 10 years of age: Karnofsky ≥ 50%; Subjects ≤ 10 years of age: Lansky scale ≥ 50%.\n* Normal organ function.\n\n  * Total bilirubin ≤ 3 times upper limit of normal\n  * AST (SGOT) ≤ 5 times upper limit of normal\n  * ALT (SGPT) ≤ 5 times upper limit of normal\n  * Serum Creatinine ≤ 2 times upper limit of normal\n  * Subjects must have the following hematologic function parameters: Hemoglobin (Hb) level \\> 8 g\u002FdL; Absolute Lymphocyte Count \\> 0.1x10\\^9\u002FL; Platelet \\> 50x10\\^9\u002FL\n* Prior therapy wash-out. At least 2 weeks or 5 half lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis.\n* Subjects' parent or legal guardian must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Autologous transplant within 6 weeks of planned CAR T cell infusion.\n* Recipient of CAR-T cell therapy outside of this protocol.\n* Active central nervous system (CNS) or meningeal involvement by tumor.\n* History of additional active malignancy other than non-melanoma skin cancer, carcinoma in situ (e.g. cervix, bladder, breast).\n* Active human immunodeficiency virus (HIV) infection.\n* Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant or breastfeeding women.\n* Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy.\n* Serologic status reflecting active hepatitis B or C infection.","1 Year","17 Years",{"count":497,"type":20},18,[254],"This study seeks to examine the efficacy and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor (CAR) targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in children with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoma. The overall goal of this study is to validate the safety profile of administration CD19-CAR T cells and describe the response rate in children with relapsed\u002Frefractory ALL or lymphoma.",[27,501],"Acute Lymphoblastic Leukemia, Pediatric",[503,504],"CAR-T cell","Pediatric","2025-03-04",{"date":152,"type":33},{"date":508,"type":33},"2024-05-01",{"date":510,"type":20},"2037-12-31",{"name":512,"class":183},"Hong Kong Children's Hospital",{"id":514,"slug":515,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":11,"sex":16,"minAge":165,"maxAge":520,"enrollmentInfo":521,"targetDuration":4,"studyType":21,"phases":522,"briefSummary":523,"conditions":524,"keywords":525,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":215},"100581436","cd30-car-t-in-the-treatment-of-cd30-positive-relapsedrefractory-lymphoma-100581436","NCT06850285","CD30 CAR-T in the Treatment of CD30 Positive Relapsed\u002FRefractory Lymphoma","Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor Gene Modified T Cells Targeting CD30 in the Treatment of CD30 Positive Relapsed\u002FRefractory Lymphoma","Inclusion Criteria:\n\n* Age≥15 years and ≤80years，female and male；\n* CD30+ lymphocyte malignancies;\n* CD30 expression \\>10% by immunohistochemistry；\n* At least 1 measurable lesion can be measured according to theLugano 2014 evaluation criteria;\n* Not suitable for autologous hematopoietic stem cell transplantation or recurrence after autologous hematopoietic stem cell transplantation;\n* Not suitable for BV treatment or relapse after BV treatment, and the expression of CD30 was confirmed by histology;\n* The estimated survival time ≥3 months;\n* ECOG performance status 0-2，KPS\\>60%;\n* Sufficient organ function：ALT，AST≤2.5×ULN，patients with liver invasion can be relaxed to ≤ 5 x ULN；serum total bilirubin\\\u003C34 μmol\u002FL；creatinine clearance rate\\>30 mL\u002Fmin；EF≥40%；No pericardial effusion and obvious arrhythmia；SpO2≥92%；\n* ALC ≥0.5×109\u002FL，PLT\\>30×109\u002FL，Hb\\>80 g\u002FL and subjects had apheresis venous access and no contraindications for blood cell separation;\n* MRI showed no central involvement of lymphoma;\n* Patients with fertility must be willing to be able to use reliable contraceptive measures ;\n* The subject or legal guardian can understand and voluntarily sign the written informed consent.\n\nExclusion Criteria:\n\n* Lymphoma-associated hemophagic cell syndrome;\n* Pregnant or lactating women, and women who have a pregnancy plan within six months;\n* Hepatitis B（HBsAg、HBsAb、HBeAg、HBeAb、HBcAb），Hepatitis C（Anti-HCV），Anti-HIV Ⅰ\u002FⅡ and anti-TP positive（Hepatitis B DNA test is negative except）;\n* Suffered from other malignant tumors, except for for skin basal cell carcinoma, skin squamous cell carcinoma and cervical carcinoma in situ undergoing the radical treatment;\n* Received Anti-CD30 Ab therapy within 4 weeks before enrollment;\n* Unresolved \\> Grade 1 non-hematologic toxicity associated with any prior treatments;\n* Active uncontrolled bleeding or a known bleeding diathesis;\n* Autologous hematopoietic stem cell transplantation was performed within 6 weeks;\n* Uncontrollable active bacterial or fungal infection；\n* Known allergy to the study drug and its components;\n* Suffer from active autoimmune diseases that require systemic treatment ;\n* Persons with mental or mental illness who cannot cooperate with treatment and efficacy evaluation;\n* Participated in other clinical studies within 1 months prior to this study;\n* History of allogeneic hematopoietic stem cell transplantation;\n* patients with any condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject.","80 Years",{"count":41,"type":20},[254],"The is a prospective, open-label, dose-climbing clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r\u002Fr CD30+ lymphoma. Plan to recruit 15 subjects with r\u002Fr CD30+ lymphoma。",[27],[526],"CD30 CAR-T; lymphoma;","2025-02-23",{"date":529,"type":33},"2025-02-27",{"date":531,"type":20},"2025-09-05",{"date":533,"type":20},"2028-06-01",{"name":535,"class":183},"Shanxi Bethune Hospital",{"id":537,"slug":538,"hasResults":11,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":21,"phases":545,"briefSummary":546,"conditions":547,"keywords":548,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":562},"100424513","phase-1-phase-ib-clinical-study-of-keynatinib-100424513","NCT04807881","Phase Ib Clinical Study of Keynatinib","An Exploratory Clinical Study of Keynatinib in Relapsed\u002FRefractory B-cell Lymphoma","Inclusion Criteria:\n\n1. Unlimited gender, age ≥ 18 years (including critical value)-Cohort 1\u002F2\u002F3;\n2. Voluntarily participate in the study and sign the ICF, follow the trial treatment protocol and interview plan-Cohort 1\u002F2\u002F3;\n3. The subject's disease diagnosis meets all of the following conditions:\n\n   Cohort 1:\n   1. Primary central nervous system lymphoma (PCNSL) confirmed by pathology;\n   2. For relapsed or refractory PCNSL, at least first line treatment must be given to Central Nervous System (CNS) lesions;\n   3. Brain Magnatic resonance Imaging (MRI) or Computerized tomography (CT) shows solid lesions of PD;\n\n   Cohort 2:\n   1. CLL\u002FSLL diagnosed according to IWCLL 2008 standards;\n   2. Refractory or relapsed CLL\u002FSLL that previously received at least first-line systemic treatment. First-line treatment is defined as at least 2 cycles of standard protocol or clinical trial research protocol completed based on current guidelines;\n   3. Accord with at least one indication of CLL \u002F SLL that requiring treatment;\n   4. There is medical record confirming that it is invalid or Progression Disease occurs after response for the latest treatment;\n   5. CT \u002FMRI shows measurable lesions, which is defined as at least one lymph node with a maximum axis of more than 1.5 cm and with 2 measurable vertical dimension;\n   6. It is allowed to include the patients with a stable condition involving the central nervous system;\n\n   Cohort 3:\n   1. Mantle cell lymphoma diagnosed by histopathology: including that t (11; 14) (q13; q32) positive by cytogenetic test and \u002F or cyclin D1 highly expressed by immunohistochemistry;\n   2. Who have been pretreated with \\> 1 but failed in ≤ 3 different chemotherapies and \u002F or targeted drugs treatment.\n   3. There is a medical record confirming that it is invalid or Progression Disease occurs after response for the latest treatment;\n   4. CT \u002F MRI shows measurable lesions, which is defined as the longest diameter (of ≥1 lymph node) \\> 1.5 cm, and 2 vertical diameters is clearly measurable;\n   5. It is allowed to include the patients with a stable condition involving the central nervous system;\n4. When screening, the status score of Eastern Cooperative Oncology Group (ECOG) is 0 to 2 points-Cohort 1\u002F2\u002F3;\n5. Estimated survival time ≥ 4 months-Cohort 1\u002F2\u002F3;\n6. Subjects have appropriate organ functions, the main organ functions meet the following criteria:\n\n   1. Blood routine: Neutrophil absolute value ≥ 1.0(in cohort1, 0.75 in cohort 2\u002F3)×109 \u002FL, platelet ≥ 75(in cohort1, 50 in cohort 2\u002F3, 30×109\u002FL are acceptable if CLL patients have bone marrow involvement, transfusion-dependent thrombocytopenia is excluded )×109 \u002FL, hemoglobin ≥ 80 g\u002FL(in cohort1). \\[No blood transfusion and hematopoietic stimulating factor are used within 21 days (7 days in cohort 2\u002F3) before the first administration-Chort1\\];\n   2. Blood biochemistry: Total bilirubin (TBIL) ≤ 2 × ULN (unless diagnosed as Gilbert syndrome), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 × ULN; serum creatinine ≤ 2 × ULN or creatinine clearance rate ≥ 50 ml \u002F min (calculated according to Cockcroft Gault formula)-Cohort 1\u002F2\u002F3;\n   3. Coagulation function: International Standardized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN-Cohort 1\u002F2\u002F3;\n7. Fertile female subjects must agree to use contraceptives with an annual failure rate of \\\u003C 1% or maintain abstinence (avoid heterosexual intercourse) during the study and at least 90 days after the last administration of the study drug. Contraceptive methods with an annual failure rate of \\\u003C1% includes bilateral tubal ligation, male sterilization, proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing IUD (intrauterine devices), and copper-containing IUD. Male subjects must be sterilized by vasectomy or barrier contraception, and female partners should use the effective contraceptives as described above. In addition, male subjects are not allowed to donate sperm within 90 days after the last administration-Cohort 1\u002F2\u002F3.\n\nExclusion Criteria:\n\n* Cohort 1: R\u002FR-PCNSL\n\n  1. PCNSL is pathologically diagnosed as T-cell lymphoma;\n  2. Have previously received any of the following treatments:\n\n     1. Chemotherapy, targeted therapy, radiotherapy or antibody based anti-tumor therapy are used within 4 weeks before the first administration or within 5 half-lives (whichever is shorter);\n     2. Have previously received the treatment of B Cell Receptor (BCR) inhibitors (such as BTK, phosphoinositide kinase 3 kinase \\[PI3K\\] or SYK inhibitors) or BCL-2 inhibitors (such as ABT-199) or Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) or a bispecific antibody drug;\n     3. Have received Allogenetic Haematopoietic Stem Cell Transplantation (Allo-HSCT) or other organ transplants (except for those who have received ASCT more than six months);\n  3. Take ≥ 8 mg dexamethasone or equivalent daily to control lymphoma symptoms;\n  4. CNS external beam radiotherapy within 21 days before the first administration;\n  5. The systemic immunosuppressants, including cyclosporine A, tacrolimus, sirolimus and other drugs, haven't stopped 28 days before the first use of the study drug, or \\> 5 mg\u002Fday of prednisone or its equivalent has been taken for long period;\n  6. Have other malignant tumors within 3 years, except for the curable basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of cervix or breast;\n  7. Non-hematologic toxicity of the previous anti-tumor treatment has not recovered to ≤ grade 1 (except for hair loss);\n  8. Have uncontrollable or severe cardiovascular disease, including:\n\n     1. Congestive heart failure with New York Heart Association (NYHA) grade II or higher, unstable angina, myocardial infarction within 6 months before first study drug administration, or arrhythmia requiring treatment during screening, Left Ventricular Ejection Fraction (LVEF) \\\u003C50% ;\n     2. Primary cardiomyopathy (such as dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, and atypical cardiomyopathy);\n     3. Clinically significant QTc interval prolonged medical history, or the QTc interval of screening period \\> 470 ms in female, and \\> 450 ms in male;\n     4. Uncontrollable high blood pressure (on the basis of improving life style, with 2 or more antihypertensive drugs (including diuretics) that will be reasonably tolerable and sufficient for more than one month being applied, the blood pressure has not reached to the standard yet, or the blood pressure could only be effectively controlled by taking 4 or more antihypertensive drugs);\n  9. Have active bleeding within 2 months before screening or are taking anticoagulant\u002Fantiplatelet drugs, or the investigators believe that there is a clear bleeding tendency (such as esophageal varices with bleeding risk, or a locally active ulcer lesions);\n  10. Have medical history of deep vein thrombosis or pulmonary embolism;\n  11. Have medical history of stroke or intracranial hemorrhage within 6 months before taking the study drug, except for intracranial hemorrhage due to surgical sequelae;\n  12. Have clinically significant gastrointestinal abnormalities, which might affect drug intake, transport or absorption (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.);\n  13. Have serious or active infection requiring systematic anti infection treatment;\n  14. At screening, patients with active uncontrolled infection \\[such as infection that requiring intravenous antibiotic therapy, human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, etc.\\]; Note: If hepatitis B virus surface antigen (HBsAg) is positive, HBV-DNA \\\u003C 1000 cop\u002Fml, and ALT\u002FAST ≤ 2.0 × ULN can be included. HCV infection is defined as HCV-Ab positive.\n  15. Have past history of or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc;\n  16. Have undergone major surgery or have not recovered from the invasive operation within 4 weeks before taking the study drug for the first time and are not suitable for the clinical trial according to the judgment of the investigators;\n  17. Who is participating in other clinical studies or have participated in other intervention clinical trials within 4 weeks before screening;\n  18. Have history of alcohol or drug abuse;\n  19. Pregnant or lactating women;\n  20. Concomitant administration of drugs with moderate to severe inhibition or strong induction of cytochrome P450 CYP3A\n  21. Subjects determined by the investigators to be unsuitable for other reasons;\n\nCohort 2: R\u002FR-CLL\u002FSLL\n\n1. Have medical history of prolymphocytic leukemia, known medical history of Richter syndrome or currently suspected Richter transformation (patients with clinical suspicion need biopsy to exclude transformation)\n2. Have previously received any of the following treatments:\n\n   1. Chemotherapy, targeted therapy, radiotherapy or antibody-based anti-tumor therapy within 4 weeks or 5 half-lives (whichever is shorter) before the first administration;\n   2. Previous treatment with BTK, phosphoinositide kinase 3 kinase \\[PI3K\\] or SYK inhibitors or BCL-2 inhibitors (such as ABT-199) or chimeric antigen receptor T cell immunotherapy (CAR-T) or treatment with bispecific antibody drugs;\n   3. Patients who received allogeneic hematopoietic stem cell transplantation (Allo-HSCT) or other organ transplantation within the past 6 months;\n   4. Patients who received autologous hematopoietic stem cell transplantation within the past 6 months;\n3. Use of systemic corticosteroids within 7 days before the first administration of study drug, or continuous use of prednisone at or above 20 mg\u002Fday or equivalent;\n4. Other malignancies within 3 years, except for curable basal or squamous cell skin cancer, superficial bladder cancer, and carcinoma in situ of the uterine cervix or breast;\n5. Non-hematologic toxicity of the previous anti-tumor treatment has not recovered to ≤ grade 1 (except for hair loss);\n6. Have uncontrollable or severe cardiovascular disease, including:\n\n   1. Congestive heart failure with New York Heart Association (NYHA) grade II or higher, unstable angina, myocardial infarction within 6 months before first study drug administration, or arrhythmia requiring treatment during screening period, Left Ventricular Ejection Fraction (LVEF) \\\u003C50%;\n   2. Primary cardiomyopathy (such as dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, and atypical cardiomyopathy);\n   3. Clinically significant QTc interval prolonged medical history, or the QTc interval of screening period \\> 470 ms in female, and \\> 450 ms in male;\n   4. Uncontrollable high blood pressure (on the basis of improving life style, with 2 or more antihypertensive drugs (including diuretics) being applied that will be reasonably tolerable and sufficient for more than one month, the blood pressure has not reached to the standard yet, , or the blood pressure could only be effectively controlled by taking 4 or more antihypertensive drugs);\n7. Have active bleeding within 2 months before screening or is taking anticoagulant\u002Fantiplatelet drugs, or the investigators believe that there is a clear bleeding tendency (such as esophageal varices with bleeding risk, or a locally active ulcer lesions);\n8. Active and\u002For persistent autoimmune anemia and\u002For autoimmune thrombocytopenia requiring treatment (e.g., idiopathic thrombocytopenic purpura);\n9. Have medical history of deep vein thrombosis or pulmonary embolism;\n10. Have medical history of stroke or intracranial hemorrhage within 6 months before taking study drug;\n11. Have clinically significant gastrointestinal abnormalities, which might affect drug intake, transport or absorption (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.);\n12. Have active infection requiring systemic anti-infective treatment;\n13. At screening, patients with active uncontrolled infection \\[such as intravenous infection that requiring antibiotic therapy, human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, etc.\\]; Note: If hepatitis B virus surface antigen (HBsAg) is positive, HBV-DNA \\\u003C 1000 cop\u002Fml, and ALT\u002FAST ≤ 2.0 × ULN can be included. HCV infection is defined as HCV-Ab positive.\n14. Have past history of or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc;\n15. Have history of alcohol or drug abuse;\n16. Have undergone major surgery or have not recovered from the invasive operation within 4 weeks before taking the study drug for the first time and are not suitable for the clinical trial according to the judgment of the investigators;\n17. Whowill participating in other clinical studies or haveparticipated in other intervention clinical trials within 4 weeks before screening;\n18. Pregnant or lactating women;\n19. Concomitant administration of drugs with moderate to severe inhibition or strong induction of cytochrome P450 CYP3A;\n20. Subjects determined by the investigators to be unsuitable for other reasons;\n\nCohort 3: R\u002FR-MCL\n\n1. Havepreviously received any of the following treatments:\n\n   1. Chemotherapy, targeted therapy, radiotherapy or antibody based anti-tumor therapy are used within the first 4 weeks or 5 half-lives (whichever is shorter) before the first administration;\n   2. Have previously received the treatment of BTK, phosphoinositide kinase 3 kinase \\[PI3K\\] or SYK inhibitors) or BCL-2 inhibitors (such as ABT-199) or Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) or received bispecific antibody drug;\n2. Use of systemic corticosteroids at or above 20 mg\u002Fday prednisone or equivalent within 7 days before the first administration of study drug;\n3. Have other malignant tumors within 3 years, except for the curable basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of cervix or breast ;\n4. Non-hematologic toxicity of the previous anti-tumor treatment has not recovered to ≤ grade 1 (except for hair loss);\n5. Have uncontrollable or severe cardiovascular disease, including:\n\n   1. Congestive heart failure with New York Heart Association (NYHA) grade II or higher, unstable angina, myocardial infarction within 6 months before first study drug administration, or arrhythmia requiring treatment during screening period, Left Ventricular Ejection Fraction (LVEF) \\\u003C50% ;\n   2. Primary cardiomyopathy (such as dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, and atypical cardiomyopathy);\n   3. Clinically significant QTc interval prolonged medical history, or the QTc interval of screening period \\> 470 ms in female, and \\> 450 ms in male;\n   4. Uncontrollable high blood pressure (on the basis of improving life style, with 2 or more antihypertensive drugs (including diuretics) that will be reasonably tolerable and sufficient for more than one month being applied, the blood pressure has not reached to the standard yet, , or the blood pressure could only be effectively controlled by taking 4 or more antihypertensive drugs);\n6. Have medical history of deep vein thrombosis or pulmonary embolism;\n7. Have medical history of stroke or intracranial hemorrhage within 6 months before taking study drug;\n8. Have clinically significant gastrointestinal abnormalities, which might affect drug intake, transport or absorption (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.);\n9. Have serious or active infection requiring systematic anti infection treatment;\n10. At screening, patients with active uncontrolled infection \\[such as infection that requiring intravenous antibiotic therapy, human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, etc.\\]; Note: If hepatitis B virus surface antigen (HBsAg) is positive, HBV-DNA \\\u003C 1000 cop\u002Fml, and ALT\u002FAST≤ 2.0 × ULN can be included. HCV infection is defined as HCV-Ab positive.\n11. Have past history of or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe impairment of lung function, etc;\n12. Have history of alcohol or drug abuse;\n13. Have undergone major surgery or have not recovered from the invasive operation within 4 weeks before taking the study drug for the first time and is not suitable for the clinical trial according to the judgment of the investigators;\n14. Who is participating in other clinical studies or have participated in other intervention clinical trials within 4 weeks before screening;\n15. Pregnant or lactating women;\n16. Concomitant administration of drugs with moderate to severe inhibition or strong induction of cytochrome P450 CYP3A;\n17. Subjects determined by the investigators to be unsuitable for other reasons;",{"count":544,"type":20},75,[23],"The purpose of this study is to evaluate the efficacy, safety, PK characteristics in subjects with relapsed\u002Frefractory B-cell lymphoma. Furthermore, the relationship between the exposure level of Keynatinib and its efficacy and safety, the penetration rate of keynatinib in the Blood-Brain Barrier (BBB) and its PK characteristics in cerebrospinal fluid in R\u002FR-PCNSL patients, the relationship between the BTK receptor occupancy rate and the efficacy are also evaluated.",[27],[549,550,551,552],"Relapsed\u002FRefractory Primary Central Nervous System Lymphoma","Relapsed\u002FRefractory Chronic Lymphoblastic Leukemia","Relapsed\u002FRefractory Small Lymphocytic Lymphoma","Relapsed\u002FRefractory Mantle Cell Lymphoma","2025-01-19",{"date":555,"type":33},"2025-01-22",{"date":557,"type":33},"2020-09-24",{"date":559,"type":20},"2028-04-10",{"name":561,"class":40},"Medolution Ltd.",4,{"id":564,"slug":565,"hasResults":11,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":11,"sex":16,"minAge":494,"maxAge":570,"enrollmentInfo":571,"targetDuration":4,"studyType":21,"phases":573,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":592},"100475887","phase-1-tagraxofusp-in-pediatric-patients-with-relapsed-or-refractory-cd123-expressing-hematologic-malignancies-100475887","NCT05476770","Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies","A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies","Inclusion Criteria:\n\nAge\n\n* Patients must be ≥ 1 and ≤21 years of age at the time of study enrollment.\n\nDiagnosis\n\n* Relapsed and\u002For refractory hematologic malignancy (including, but not limited to, acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, mixed phenotype acute leukemia, acute undifferentiated leukemia, blastic plasmacytoid dendritic cell neoplasm, Hodgkin lymphoma, and non-Hodgkin lymphoma).\n* Tumor cells must demonstrate surface expression of CD123 at the time of enrollment by flow cytometry or immunohistochemistry, as defined by the local institution.\n\nDisease Status:\n\nMonotherapy, Part 1\n\n* Second or greater relapse; or\n* Refractory after 2 or more chemotherapy cycles; or\n* First relapse after primary chemotherapy-refractory disease; or\n* BPDCN in first relapse or refractory after 1 or more chemotherapy cycles\n\nCombination therapy, Part 2\n\n* First or greater relapse; or\n* Refractory after 2 or more chemotherapy cycles; or\n* BPDCN in first relapse or refractory after 1 or more chemotherapy cycles\n\nFor relapsed\u002Frefractory leukemia, patients must have:\n\n* \\>5% blasts in the bone marrow aspirate or biopsy by morphology or flow cytometry\n* Patients with 1% - 5% blasts are eligible for Part 2, Cohort C (only), if A single bone marrow sample with flow cytometry and at least one other test (e.g. karyotype, FISH, PCR, or NGS) shows ≥ 1% leukemic blasts and\u002For flow cytometry demonstrates a stable or rising level of disease on two serial bone marrows.\n\nFor relapsed\u002Frefractory non-Hodgkin or Hodgkin lymphoma, patients must have:\n\n* Histologic verification of relapse\n* Measurable disease documented by radiographic criteria or bone marrow\n* Patients in Part 1 may have sites of non-CNS extramedullary disease, but no CNS disease. Patients in Part 2 may have CNS disease and\u002For other non-CNS extramedullary disease. No cranial irradiation is allowed during the protocol therapy.\n* Patients with Down syndrome are eligible to participate in Part 1 only.\n\nPerformance Level\n\n* Karnofsky \\> 50% for patients \\> 16 years of age and Lansky \\> 50% for patients ≤ 16 years of age (See Appendix I for Performance Scales). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.\n\nPrior Therapy\n\n* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy, defined as resolution of all such toxicities to ≤ Grade 2 or lower per the inclusion\u002Fexclusion criteria.\n\nMyelosuppressive chemotherapy: Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. At least 14 day must have elapsed since the completion of myelosuppressive therapy. However, individuals may receive any of the following medications within 14 days without a \"wash-out period\":\n\n* Hydroxyurea: Hydroxyurea can be initiated and\u002For continued for up to 24 hours prior to the start of protocol therapy.\n* \"Maintenance-style\" therapy: therapy including vincristine (dosed a maximum of one-time weekly), oral 6-mercaptopurine, oral methotrexate (dosed a maximum of one-time weekly), intrathecal therapy (dosed a maximum of one-time weekly) and\u002For dexamethasone (dosed at ≤3 mg\u002Fm2\u002Fdose twice daily) or prednisone (dosed at ≤20 mg\u002Fm2\u002Fdose twice daily) can be continued for up to 24 hours prior to entering the study.\n* Hematopoietic stem cell transplant: Patients who have experienced their relapse after a HSCT are eligible, provided they have no evidence of acute or chronic Graft-versus-Host Disease (GVHD) and are at least 100 days post-transplant at the time of enrollment.\n* Hematopoietic growth factors: It must have been at least 7 days since the completion of therapy with granulocyte colony stimulating factor (GCSF) or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta®).\n* Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.\n* Monoclonal antibodies: Maximum of 3 half-lives of the antibody or 21 days (whichever is shorter) must have elapsed after the last dose of monoclonal antibody.\n* Immunotherapy: At least 30 days from last infusion of chimeric antigen receptor T cell (CART) therapy or tumor vaccine.\n* Radiation Therapy (XRT):\n\n  1. ≥ 84 days must have passed, from the end of therapy, if patient received prior total body irradiation (TBI).\n  2. ≥ 42 days must have passed, from the end of therapy, if patient received craniospinal irradiation (CSI).\n  3. ≥ 14 days must have passed after whole brain radiotherapy or stereotactic radiation therapy.\n  4. No washout period is required for:\n\n  i. Extramedullary site other than CNS that is a maximum 10 x 10 cm total radiation non-CNS field. If the field is \\> 10 x 10 cm, a 14-day washout period is required. ii. Local ocular radiotherapy as long as subject has measurable\u002Fevaluable disease outside the radiation port.\n* Patients that have received other non-tagraxofusp CD123 targeting agents are eligible. Patients that have previously received tagraxofusp are not eligible.\n\nOrgan Function Requirements\n\nAdequate Bone Marrow Function Defined as:\n\n* Patients should not be known to be refractory to red blood cell or platelet transfusions.\n* Blood counts are not required to be normal prior to enrollment on trial. However, platelet count must be ≥20,000\u002Fmm3 to initiate therapy (may receive platelet transfusions).\n\nAdequate Renal Function Defined as:\n\n* Patient must have a calculated creatinine clearance or radioisotope GFR ≥ 70ml\u002Fmin\u002F1.73m2 OR a normal serum creatinine based on age\u002Fgender in the chart below:\n\nMaximum Serum Creatinine (mg\u002FdL):\n\n* 1 to \\\u003C 2 years old - Male: 0.6, Female: 0.6\n* 2 to \\\u003C 6 years old - Male:0.8, Female: 0.8\n* 6 to \\\u003C 10 years old - Male: 1, Female: 1\n* 10 to \\\u003C 13 years old - Male: 1.2, Female: 1.2\n* 13 to \\\u003C 16 years old - Male: 1.5, Female: 1.4\n* ≥ 16 years old - Male: 1.7, Female: 1.4\n\nThe threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC.\n\nAdequate Liver Function Defined as:\n\n* Total bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x institutional upper limit of normal for age\n* SGPT (ALT) and SGOT (AST) must be less than 3x institutional upper limit of normal.\n* Serum albumin ≥3.2 g\u002FdL (albumin infusion independent).\n\nAdequate Cardiac Function Defined as:\n\n* Shortening fraction of ≥27% by echocardiogram, or\n* Ejection fraction of ≥ 50% by gated radionuclide study\u002Fechocardiogram.\n\nAdequate Pulmonary Function Defined as:\n\n* Pulse oximetry \\> 94% on room air (\\> 90% if at high altitude)\n* No evidence of dyspnea at rest and no exercise intolerance.\n\nReproductive Function\n\n* Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within 2 weeks prior to enrollment.\n* Female patients with infants must agree not to breastfeed their infants while on this study.\n* Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for 12 weeks after the last dose of tagraxofusp.\n\nExclusion Criteria\n\nDisease Status:\n\n* Patients with CNS disease are not eligible for Part 1.\n* Patients with isolated CNS disease are not eligible for Part 1 or Part 2.\n* Patients with isolated non-CNS disease are eligible for Part 1 and Part 2.\n\nConcomitant Medications\n\n* Corticosteroids - Patients receiving corticosteroids for disease control who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible.\n* Investigational Drugs - Patients who are currently receiving another investigational drug are not eligible. The definition of \"investigational\" for use in this protocol means any drug that is not licensed by the FDA, Health Canada or the Therapeutic Goods Administration to be sold in the countries they govern. (United States, Canada and Australia)\n* Anti-cancer Agents - Patients who are currently receiving or may receive while on therapy, other anti-cancer agents, radiation therapy or immunotherapy are not eligible \\[with the exceptions being laid out in the inclusion criteria under 'Prior Therapy'\\]. Intrathecal chemotherapy (at the discretion of the primary oncologist) may be given up to one week prior to the initiation of study treatment (day 1 therapy).\n* Anti-GVHD or agents to prevent organ rejection post-transplant - Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial. At least 4 weeks must have elapsed after the last dose of GVHD meds.\n\nInfection Criteria - Patients are excluded if they have:\n\n* Positive blood culture within 48 hours of study enrollment;\n* Fever above 38.2 within 48 hours of study enrollment with clinical signs of infection. Fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability.\n* A positive fungal culture within 30 days of study enrollment.\n* Active fungal, viral, bacterial, or protozoal infection requiring IV treatment. Chronic prophylaxis therapy to prevent infections is allowed.\n* Patients will be excluded if they have a known allergy to any of the drugs used in the study.\n* Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with the protocol treatment or procedures, interfere with consent, study participation, follow up, or interpretation of study results.\n* Patients with DNA fragility syndromes (such as Fanconi anemia, Bloom syndrome) are excluded.","21 Years",{"count":572,"type":20},54,[23],"Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed\u002Frefractory hematologic malignancies.\n\nThe mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells.\n\nThe rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date.\n\nThis trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy.\n\nThe goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients.\n\nAbout 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.",[392,576,16,577,578,579,27,28,580,581,582],"AML","BPDCN","MDS","Lymphoblastic Lymphoma","Hodgkin Lymphoma","Mixed Phenotype Acute Leukemia","Acute Undifferentiated Leukemia","2024-12-04",{"date":585,"type":33},"2024-12-06",{"date":587,"type":33},"2022-11-11",{"date":589,"type":20},"2027-11-11",{"name":591,"class":183},"Therapeutic Advances in Childhood Leukemia Consortium",31,{"id":594,"slug":595,"hasResults":11,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":601,"enrollmentInfo":602,"targetDuration":4,"studyType":21,"phases":604,"briefSummary":606,"conditions":607,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":215},"100562910","phase-4-axicabtagene-ciloleucel-for-consolidation-after-first-line-treatment-of-high-risk-large-b-cell-lymphoma-100562910","NCT06609304","Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma","Prospective Clinical Study of Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma","axi-cel","Inclusion Criteria:\n\n1. Understand and voluntarily sign the informed consent form;\n2. 18-70 years of age (inclusive);\n3. Previously untreated CD19-positive large B-cell lymphoma;\n4. Anticipated survival ≥12 weeks;\n5. Adequate bone marrow reserve prior to apheresis\n6. Appropriate organ function:\n7. Eastern Cooperative Oncology Group (ECOG) Physical Status Score of 0 or 1; 8. Absence of CNS lymphoma;\n\n9\\. Negative blood\u002Furine pregnancy test in women of childbearing age.\n\nExclusion Criteria:\n\n1. History of allergy to any of the components of the cell product;\n2. History of stem cell transplantation;\n3. History of organ transplantation;\n4. Presence of active infections;\n5. Current or history of central nervous system disorders;\n6. Previous treatment with other modified T-cell therapy;\n7. Previous treatment with anti-CD19\u002FCD3 or other anti-CD19 therapies;\n8. Malignancies other than those indicated for this trial;\n9. History of any prior systemic immune checkpoint therapy;\n10. History of short-acting cell growth factors or haematopoietic agonists\u002Fstimulants ;\n11. History of a live vaccine within 3 months prior to screening;.","70 Years",{"count":603,"type":20},20,[605],"PHASE4","The goal of this clinical trial is to learn if Axicabtagene Ciloleucel (axi-cel) works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of axi-cel treatment. The main questions it aims to answer are:\n\n* Does axi-cel treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment?\n* What medical problems do participants have when receiving axi-cel treatment?\n\nIn this investigator-initiated, single-arm clinical trial, participants will:\n\n* Receive atezolizumab treatment at 2.0×10\\^6 cells\u002FKg as a one-time therapy.\n* Visit the clinic as instructed for checkups and tests.",[27],"2024-10-09",{"date":610,"type":33},"2024-10-15",{"date":612,"type":20},"2024-09-30",{"date":614,"type":20},"2027-08-31",{"name":616,"class":183},"Zhengzhou University",{"id":618,"slug":619,"hasResults":11,"nctId":620,"briefTitle":621,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":625,"conditions":626,"keywords":628,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":4},"100560127","a-real-world-study-on-extranodal-lymphoma-100560127","NCT06573099","A Real-World Study on Extranodal Lymphoma","Inclusion Criteria:\n\n1. Age ≥ 18 years (including 18 years old).\n2. Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined.\n3. Patients who have received systematic clinical treatment.\n4. Patients with measurable lesions, at least containing one effective evaluation of efficacy.\n\nExclusion Criteria:\n\n1. Patients who only receive supportive treatment.\n2. Patients who cannot obtain effective evaluation data of efficacy.",{"count":624,"type":20},5000,"The aim of this study is to prospectively collect clinical information on patients with extranodal lymphoma, and to explore the best therapeutic strategies in the real-world population.",[93,27,118,627,228],"Extranodal Lymphoma",[629,630,349],"LYMPHOMA","EXTRANODAL","2024-08-23",{"date":633,"type":33},"2024-08-27",{"date":635,"type":20},"2024-09-01",{"date":637,"type":20},"2029-09-01",{"name":639,"class":183},"Ruijin Hospital",{"id":641,"slug":642,"hasResults":11,"nctId":643,"briefTitle":644,"officialTitle":645,"acronym":4,"eligibilityCriteria":646,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":649,"conditions":650,"keywords":652,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":184},"100527009","relmacabtagene-autoleucel-in-hematologic-malignancies-100527009","NCT06142188","Relmacabtagene Autoleucel in Hematologic Malignancies","A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel","Inclusion Criteria:\n\n1. Signed informed consent\n2. Patients who have been treated with Relma-cel, including those who have received off-label products;\n3. If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study.\n\nExclusion Criteria:\n\n1.Patients who have been treated with Relma-cel and then have been treated with other CAR-T products.",{"count":648,"type":20},150,"To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world",[27,84,651],"Follicular Lymphoma",[653,654],"Relmacabtagene Autoleucel","Chimeric antigen receptor T cells","2023-11-15",{"date":657,"type":33},"2023-11-21",{"date":659,"type":20},"2023-12-28",{"date":661,"type":20},"2038-12-31",{"name":663,"class":40},"Shanghai Ming Ju Biotechnology Co., Ltd.",{"id":665,"slug":666,"hasResults":11,"nctId":667,"briefTitle":668,"officialTitle":669,"acronym":4,"eligibilityCriteria":670,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":671,"targetDuration":4,"studyType":195,"phases":4,"briefSummary":672,"conditions":673,"keywords":677,"overallStatus":234,"whyStopped":4,"lastUpdateSubmitDate":679,"lastUpdatePostDateStruct":680,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":215},"100503374","omic-technologies-applied-to-the-study-of-b-cell-lymphoma-for-the-discovery-of-diagnostic-and-prognosis-biomarkers-100503374","NCT05834426","Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers","Omic Technologies Applied to the Study of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers","Inclusion Criteria:\n\n* 18 years and older;\n* Both sexes;\n* Patients with confirmed histopathological diagnosis of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma;\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2;\n* Patient intending to receive full-dose treatment (Monoclonal antibodies plus anthracycline based combination chemotherapy);\n* Staged with PET-CT or CT.\n\nExclusion Criteria:\n\n* Patients with comorbidities that may interfere with the interpretation of the results (CKD in dialysis phase, Autoimmune diseases, uncontrolled Diabetes Mellitus (DM), symptomatic Heart Failure (CHF), HIV positive, positive serology for hepatitis B and C);\n* Patients requiring multiple blood transfusions (4 or more blood components for the same period or cause);\n* Pregnant women;\n* First-line treatment in another institution;\n* Diffuse transformed Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma",{"count":418,"type":20},"The goal of this observational study is to determine the plasma metabolomic profile in diffuse large B-cell lymphoma and high-grade B lymphomas patients before, during and after treatment by ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)",[27,446,674,200,228,675,676],"Cancer","Non Hodgkin Lymphoma","Metabolomics",[678],"Metabolomic Analysis","2023-06-19",{"date":681,"type":33},"2023-06-22",{"date":683,"type":20},"2023-09-01",{"date":685,"type":20},"2026-08-31",{"name":687,"class":183},"Sociedad de Lucha Contra el Cáncer del Ecuador"]